Sarepta Therapeutics: Reports of Its Demise Appear ‘Greatly Exaggerated’

From Stocks To Watch Today
January 11, 2017 - 10:37am

Sarepta Therapeutics (SRPT) gained more than 20\% yesterday after the company provided an update on the uptake of its Duchenne muscular dystrophy treatment that seemed to allay some investor fears. RBC's Simos Simeonidis and Hong Zheng note that "reports of EXONDYS51's demise appear greatly exaggerated." They explain:



Continue reading this article »